Novel statins: Pharmacological and clinical results

Chiara Bolego, Andrea Poli, Andrea Cignarella, Alberico L. Catapano, Rodolfo Paoletti

Research output: Contribution to journalArticlepeer-review


Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile. In particular, they show a high potency in decreasing LDL-C and their catabolism is not mediated by the cytochrome P-450 3A4, thus reducing the potential for drug-drug interaction and improving the management of blood cholesterol. As the magnitude of LDL-C reduction is directly associated with the decrease in the incidence of myocardial infarction and mortality for CAD, statins with increased LDL-C lowering potency may ensure the achievement of target LDL-C levels and offer a more aggressive cholesterol control, further improving CAD morbidity and mortality.

Original languageEnglish
Pages (from-to)251-257
Number of pages7
JournalCardiovascular Drugs and Therapy
Issue number3
Publication statusPublished - 2002


  • HMG-CoA reductase inhibitors
  • NK-140
  • Novel statins
  • Pitavastatin
  • Pleiotropic effects
  • Rosuvastatin
  • ZD 4522

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Novel statins: Pharmacological and clinical results'. Together they form a unique fingerprint.

Cite this